Urological disorders immunotherapeutic - AmVac

Drug Profile

Urological disorders immunotherapeutic - AmVac

Alternative Names: AMV 110; ProstaVac

Latest Information Update: 29 May 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vakcina Kft
  • Developer AmVac
  • Class Bacterial vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Benign prostatic hyperplasia; Prostatitis

Most Recent Events

  • 29 May 2015 No recent reports on development identified - Phase-II for Benign prostatic hyperplasia and Prostatitis in Hungary (IM)
  • 29 Feb 2012 AmVac's immunotherapeutic for urological disorders is available for partnering in USA, Japan. http://amvac.eu/v2/
  • 05 Feb 2007 Phase-II clinical trials in Benign prostatic hyperplasia in Hungary (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top